ArticleJACC. Case reports2026
Novel Caval Valve Implantation in a Patient With Symptomatic Tricuspid Regurgitation and Right Heart Failure.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Valve: Heterotopic Tricuspid Intervention as a Therapy for the Failing Right Heart.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricuspid regurgitation (TR) is crucial for recurrent cardiac decompensation. Heterotopic transcatheter approaches enable symptomatic treatment of TR in patients who are ineligible for surgery or transcatheter edge-to-edge repair. The TRICENTO G2 prosthesis is a transcatheter bicaval valved stent graft, not yet approved for the market. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: To the best of our knowledge, this is the first published case of successful TRICENTO G2 transcatheter heart valve implantation, performed as compassionate use in an 81-year-old man with symptomatic TR following multiple interventions. No major complications occurred during the procedure, and a short-term functional improvement in right ventricular function resulted. Given intermittent third-degree atrioventricular block, leadless pacemaker implantation was conducted subsequently. DISCUSSION: The TRICENTO G2 represents a promising treatment option for symptomatic TR. However, wise patient selection and vigilant postprocedural observation are essential. NOVELTY: The implementation of the TRICENTO G2 may expand our interventional armamentarium for treating TR. TAKE-HOME MESSAGE: The TRICENTO G2 may improve tailored treatment of patients with symptomatic TR and right ventricular dysfunction who are ineligible for approved interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.